Demystifying Prothena Corp: Insights From 5 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Prothena Corp (NASDAQ:PRTA) has been reviewed by 5 analysts over the past three months, with ratings ranging from bullish to somewhat bullish. The average 12-month price target is $97.6, with a high of $129.00 and a low of $62.00, reflecting a 7.92% decrease from the previous average. Analysts from firms including Cantor Fitzgerald, Deutsche Bank, and JMP Securities have adjusted their ratings and price targets. Prothena's financials show a significant revenue growth rate of 5494.33% as of September 30, 2023, a net margin of 25.81%, an ROE of 3.65%, an ROA of 2.99%, and a low debt-to-equity ratio of 0.02.
January 09, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prothena Corp has received mixed analyst ratings but maintains a positive outlook with a high average price target of $97.6 despite a recent decrease. The company's strong financial performance, including exceptional revenue growth and solid profitability metrics, may bolster investor confidence.
The mixed analyst ratings suggest some uncertainty, but the overall positive price target and strong financial indicators such as high revenue growth, net margin, ROE, and ROA, coupled with low debt, provide a strong case for potential short-term positive impact on PRTA's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100